April 8, 2024: MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Lyon, France, April 8 2024 –7.20 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients [...]

March 19, 2024: MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells. The new data strengthens previous promising findings shared at the Society for Immunotherapy of Cancer (SITC) conference in November 2023 and [...]